Versuchen GOLD - Frei
Unani Medicine: At crossroads of tradition and modernity
Express Pharma
|October 2025
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
Unani medicine has been practiced in India for centuries but in recent years, the global health and wellness trend has brought renewed attention to Unani and other traditional systems. Once viewed largely as a heritage stream of healthcare, it is now repositioning itself as a modern, evidence-driven system with aspirations for global recognition. The sector is proactively investing in analytical technologies, pharmacological studies, and clinical evaluations to build a body of data that strengthens both credibility and consumer confidence.
The industry is witnessing a significant change to further strengthen and boost the growth of Unani medicine not only in India but across globe. The three major stakeholders of the industry - manufacturers, academia and CCRUM are collaborating and exploring various initiative that would help in gaining credibility and accessibility of Unani medicine.
From traditional to modern, evidence-based products
Today, Unani stands at a transformative moment where its future is shaped not only by the weight of its tradition but also by the demands of modern science, global regulation, and discerning consumers. “Unani medicine today stands at a unique crossroads where tradition and modern science can enrich one another,” reflects Abdul Majeed, Chairman & Trustee, Hamdard. “The journey ahead is about harmonising timeless wisdom with rigorous evidence to earn both trust and global acceptance,” he adds.
Unlike earlier decades, where classical formulations were reproduced with little alteration, today's Unani manufacturers are increasingly turning to evidence-based validation.
“This shift is not cosmetic—it is strategic,” said Majeed. He further elaborated that the industry is currently focusing on credibility and accessibility to ensure Unani is scientifically validated at the same time making it affordable for wider acceptance, especially among younger, wellness-driven consumers.
Diese Geschichte stammt aus der October 2025-Ausgabe von Express Pharma.
Abonnieren Sie Magzter GOLD, um auf Tausende kuratierter Premium-Geschichten und über 9.000 Zeitschriften und Zeitungen zuzugreifen.
Sie sind bereits Abonnent? Anmelden
WEITERE GESCHICHTEN VON Express Pharma
Express Pharma
Speed and flexibility play a critical role in how we compete with larger global players
Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma
6 mins
January 2026
Express Pharma
Vizag rising: Shaping India's pharma future
At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth
9 mins
January 2026
Express Pharma
Future of pharma: Trends, challenges & AI
Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies
2 mins
January 2026
Express Pharma
Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments
When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.
1 mins
January 2026
Express Pharma
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare
3 mins
January 2026
Express Pharma
The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.
6 mins
January 2026
Express Pharma
Results win customers. Leadership discipline keeps them
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
3 mins
January 2026
Express Pharma
INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF
India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge
8 mins
January 2026
Express Pharma
PRUV® -The original Sodium Stearyl Fumarate
JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago
5 mins
January 2026
Express Pharma
Odisha's pharma pitch
The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury
5 mins
January 2026
Listen
Translate
Change font size
